Interesting take on Novo Nordisk.
Lilly lost me, because I am allergic to their preservative. Didn’t realize that until I went on the pump, I thought the burning sensation was just part of the injection.
I find Novolog much easier on the body, and reacts a bit better — I use slightly less insulin on Novolog, though that might be a function of the preservative reaction.
A really good organization is the Diabetes Exercise and Sports Association. I was just wandering around the forums, and there are several active Type 2’s that talk about being recently diagnosed, and shocked to be diagnosed as they were physically active.
Very interesting.
I went to insulin early, and have never regretted it. Frankly, I have had better control and freedom. It’s even more true since I went to the pump.
Resistance to Insulin Therapy Among Patients and Providers
Patient and provider attitudes differ significantly across countries, controlling for individual characteristics. Patients rate the clinical efficacy of insulin as low and would blame themselves if they had to start insulin therapy. Self-blame is significantly lower among those who have better diet and exercise adherence and less diabetes-related distress.
See http://diabetestalkfest.com/blog/?cat=1 for Talkfest’s introduction to one of their users blogging about the Guardian.
By the way, just from the first entry, I pass.
I like my hot tub too much to have to deal with $40.00 sensors.
Not to mention the pool, which is miserable this time of year.
The HooK: DR. HOO- Byetta: A new weapon, but not a gun
DR. HOO- Byetta: A new weapon, but not a gun
However, the article is inaccurate when it talks about Symlin.
Here’s another attempt at a continuous glucose monitoring device.
Glucon announced last week the recent trial results of its flagship product, Aprise, a continuous, non-invasive, glucose monitoring device. The data was presented by Glucon V.P. of R&D Dr. Benny Pesach at the Diabetes Technology Society Standards Workshop on November 10, 2005 at the Fifth Annual Diabetes Technology Meeting in San Francisco.
Here’s another attempt at a continuous glucose monitoring device.
Glucon announced last week the recent trial results of its flagship product, Aprise, a continuous, non-invasive, glucose monitoring device. The data was presented by Glucon V.P. of R&D Dr. Benny Pesach at the Diabetes Technology Society Standards Workshop on November 10, 2005 at the Fifth Annual Diabetes Technology Meeting in San Francisco.
I will admit I “cheated” in a way, I wrote my blog entry last night, and kept it inactive until I got up this morning.
I wanted to make sure that I remembered and got the entry up. Welcome to all the commenters, I’m going to get to everyone else’s blog this evening after I’ve gotten my workout in and have eaten dinner.
Sorry about the commenting being off. I wish someone had told me. I thought I had it fixed, but it just wouldn’t stay that way.
Hopefully the commenting is back on.
I will admit I “cheated” in a way, I wrote my blog entry last night, and kept it inactive until I got up this morning.
I wanted to make sure that I remembered and got the entry up. Welcome to all the commenters, I’m going to get to everyone else’s blog this evening after I’ve gotten my workout in and have eaten dinner.
Sorry about the commenting being off. I wish someone had told me. I thought I had it fixed, but it just wouldn’t stay that way.
Hopefully the commenting is back on.